Epilepsy Res. 2001;44(2–3):197–206.FK228 cost PubMedCrossRef 3. Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine selleck screening library acetate. In: Shorvon S, Perucca E, Engel J, editors.

The treatment of epilepsy. 3rd ed. Oxford: Blackwell Publishing; 2009. p. 485–98.CrossRef 4. Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53(6):935–46.PubMedCrossRef 5. Falcao A, Maia J, Almeida L, Mazur D, Gellert M, Soares-da-Silva P. Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2–093), a new voltage-gated sodium channel blocker. Biopharm Drug Dispos. 2007;28(5):249–56.PubMedCrossRef 6. Almeida L, Potgieter JH, Maia J, Potgieter MA, Mota F, Soares-da-Silva P. Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment. Eur J Clin Pharmacol. 2008;64(3):267–73.PubMedCrossRef 7. Almeida L, Minciu I, Nunes T, Butoianu N, Falcao A, Magureanu SA, et al. Pharmacokinetics, efficacy, and tolerability of eslicarbazepine acetate in children

and adolescents with epilepsy. J Clin Pharmacol. 2008;48(8):966–77.PubMedCrossRef 8. Maia J, Almeida L, Falcão A, Soares E, Mota F, Potgieter JH, et al. Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate. Int J Clin Pharmacol Ther. 2008;46(3):119–30.PubMed 9. Perucca E, Elger C, Halasz P, Falcao A, Almeida L, Soares-da-Silva P. selleck inhibitor Pharmacokinetics of eslicarbazepine acetate at steady-state in adults with partial-onset seizures. Epilepsy Res. 2011;96(1–2):132–9.PubMedCrossRef 10. Pires N, Palma N, Loureiro AI, Bonifacio MJ, Wright LC, Soares-da-Silva P. Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the maximal electroconvulsive shock test in the mice. Epilepsia. 2011;52(Suppl. 6):118. 11. Torrao L, Machado R, Pires N, Palma N, Bonifacio MJ, Wright LC, et al. Effects of eslicarbazepine acetate, eslicarbazepine, carbamazepine and oxcarbazepine in the 6-HZ psychomotor seizure model

in the mice. Epilepsia. 2011;52(Suppl. 6):118–9. 12. Pekcec A, Potschka H, Soares-da-Silva P. Effects of eslicarbazepine acetate and its metabolites in the corneal kindling model of epilepsy. Epilepsia. 2011;52(Suppl. 6):257. 13. Soerensen J, Pekcec A, Potschka H, Soares-da-Silva P. The effects of eslicarbazepine acetate in the amygdala kindling Ketotifen model of temporal lobe epilepsy. Epilepsia. 2011;52(Suppl. 6):257. 14. Sierra-Paredes G, Sierra-Marcuno G, Loureiro AI, Wright LC, Soares-da-Silva P. Effects of eslicarbazepine acetate on acute and chronic latrunculin A-induced seizures and extracellular amino acid levels in the mouse hippocampus. Epilepsia. 2011;52(Suppl. 6):119. 15. Hebeisen S, Brady K, Konrad D, Soares-da-Silva P. Inhibitory effects of eslicarbazepine acetate and its metabolites against neuronal voltage-gated sodium channels. Epilepsia. 2011;52(Suppl. 6):257–8. 16. Brady K, Hebeisen S, Konrad D, Soares-da-Silva P.